CEO, Pharmaxis
Stories naming Dr Alan Robertson. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures announces it has fully wound down its 1998 biotech fund with returns in the top quartile of US peers, recalling portfolio listings, Dynamic Hearing's sale to Wolfson, and its $122.5m fourth fund.
Pharmaxis announced its Aridol Phase III asthma diagnostic trial has enrolled first patients across 28 US sites, with FDA marketing authorisation planned for 2006.
Australian drug developer Pharmaxis has won NASDAQ approval to trade its ADRs under ticker PXSLY, issuing no new shares; SEC registration is expected around 26 August 2005 before trading begins.
Also GBS Ventures·GBS Ventures